Pair of rare royal pistols to be sold at auction
A pair of rare pistols from the private collection of an 18th Century prince are to be sold at auction later.
The guns were owned by Prince Augustus Frederick, the first Duke of Sussex, the sixth son of King George III.
They were made in the 1790s by the esteemed Spanish gunsmith Francisco Targarona and are believed to have been given to the prince as a diplomatic gift.
The pair are estimated to fetch between £20,000 and £30,000 at a special sale of medals and coins, arms and armour at Woolley & Wallis, in Salisbury.
The duke was well liked and noted for championing societal freedom and reform.
He was also known for his large weapons collection, which was put up for auction on his death in 1843, including the pistols.
The guns are Spanish 22 bore convertible 'Madrid' lock pistols, which date from about 1795.
They are highly decorative, with geometric and floral accents, and can be fitted together to create a short, single gun.
They are housed in a fitted mahogany case with velvet lining. On the outside, the case has an oval silver plate on its lid engraved "Purchased at the sale of His Royal Highness the Duke of Sussex, 1845".
Ned Cowell, head of arms and armour at Woolley & Wallis, said the selling the guns was a privilege.
"We are honoured to be offering such an outstanding pair of pistols by such a distinguished gunmaker and with such a historic background," he added.
Other items in the sale include a selection of military medals, rare coins, swords, cannons and a coronation robe worn in 1937 and in 1953.
Follow BBC Wiltshire on Facebook, X and Instagram. Send your story ideas to us on email or via WhatsApp on 0800 313 4630.
'Very rare' five-neck guitars to be sold at auction
Titanic pocket watch could sell for £50k at auction
Sport commentator's career keepsakes sold
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Blumhouse Acquiring ‘Saw' Rights From Twisted Pictures
EXCLUSIVE: In a deal that will bring James Wan back in touch with the mega horror IP he first created, we hear from several sources that Blumhouse is acquiring the perspective rights to Twisted Pictures' portion of the Saw franchise. In short, Blumhouse is essentially taking over the IP's ownership from Twisted's Mark Burg and Oren Koules. Lionsgate will continue to be involved as a partner, and in fact owns 50% of the franchise. More from Deadline 'Phasmophobia' Film In The Works: Blumhouse To Adapt Paranormal Horror Game Octavia Spencer Returning For Blumhouse's 'Ma' Sequel Blumhouse Announces First Spanish Language Original Film 'No Me Sigas' From Directors Ximena and Eduardo García Lecuona As of this time, there isn't development on another movie yet. Wan directed the first Saw movie in 2004 and co-wrote with Leigh Whannell. Wan remained an EP on remaining Saw movies. Saw follows the notorious serial killer John 'Jigsaw' Kramer and his cronies. Instead of killing his victims, he traps them in life-threatening tests and games as they try to survive through physical or psychological torture. The Saw franchise not only grossed over $1 billion at the global box office from ten movies, but spawned comic books, video games, theme park attractions, toys, masks and clothing. The first Saw movie opened to $18.6M and made $56M domestic, $104M worldwide. There was a Saw XI movie in development that was previously scheduled for September 2025. However, the project was stalled. Lionsgate and the producers of the Saw franchise didn't see eye-to-eye on the eleventh movie. Saw XI scribes Patrick Melton and Marcus Dunstan turned in a draft in 2024 with Saw X director Kevin Greutert attached to direct. His 2023 version opened to $18.3M domestic, finaled at $53.6M stateside and went north of $112M global. Best of Deadline List Of Hollywood & Media Layoffs From Paramount To Warner Bros Discovery To CNN & More 2025 TV Cancellations: Photo Gallery 2025-26 Awards Season Calendar: Dates For Tonys, Emmys, Oscars & More
Yahoo
2 hours ago
- Yahoo
NM attorney general and two manufacturers cap diabetes drug costs in settlements
A pharmacy manager retrieves a bottle of antibiotics. (Photo by) Under settlement agreements reached earlier this year and announced by New Mexico Attorney General Raúl Torrez on Wednesday, two insulin manufacturers have committed to make the diabetes treatment cheaper for New Mexicans. 'These are huge wins for New Mexicans who have struggled with the outrageous cost of insulin,' Torrez said in a statement. 'These agreements will help people stop rationing medication, avoid financial hardship, and focus on staying healthy. We are holding drug manufacturers accountable and making access to life-saving treatment more equitable.' New Mexico Department of Justice spokesperson Lauren Rodriguez told Source NM that the agreements provide insured patients who might have a high deductible or copay the option to pay cash instead of using their insurance, and to pay no more than $35 for a monthly supply of insulin, Rodriguez said. The New Mexico state law enacted in 2020 that caps insulin costs at $25 remains in full force and is not preempted or replaced by the new settlements, Rodriguez said. Instead, the agreements are 'additive protections mainly aimed at helping cash-paying and uninsured patients, while deferring to state law when it offers better pricing,' she said. As many as 207,600 adults in New Mexico, or approximately 11% of the state's adult population, have diabetes, according to the American Diabetes Association. Without the caps, patients in other states could pay $150 per month or more, especially if they require multiple variations of the drug, Stateline reports. More states are doing what they can to cap insulin costs High out-of-pocket costs have historically forced many patients to choose between buying insulin and meeting other basic needs, NMDOJ said in a news release. The settlements result from the agency's independent investigations into insulin pricing practices, NMDOJ said. The state's agreement with Sanofi-Aventis U.S. LLC, signed on April 18, requires the company to maintain its Insulins ValYou Savings Program, which allows patients who pay out-of-pocket to receive a month's supply for $35. The Sanofi settlement also requires it to maintain its Patient Connection Program, which allows uninsured patients who aren't eligible for Medicaid and whose annual household income is at or below 400% of the federal poverty line to receive insulin for free. Under the settlement, Sanofi must also provide patients live phone and translation support in Spanish, Hmong, Somali and Mandarin Chinese; and participating pharmacies will receive training to help patients enroll in affordability programs. The settlement with Novo Nordisk Inc., signed on May 19, requires the company to maintain its MyInsulinRX Program, which offers diabetes patients the option to pay $35 or less for a monthly prescription. Under the agreement, Novo Nordisk must also continue its Patient Assistance Program, which offers insulin for free. The settlement also requires Novo Nordisk to notify pharmacies about available discounts at the point of sale, help patients enroll on the spot and offer live phone and website chat support in Spanish. Reporter Danielle Prokop contributed reporting to this story. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Bloomberg
4 hours ago
- Bloomberg
Spain Makes First Payment in Lengthy Fight Over Renewable Energy
The Spanish government made its first payment as a result of an arbitration decision in 2021 around the country's move to change investor incentives tied to renewable energy projects, following a number of lengthy legal battles between Spain and various creditors. An entity called Blasket Renewable Investments, which petitioned a claim against the country in the US, notified a US federal court on Wednesday that Spain had 'fully satisfied' a final judgment ordering the payment, court documents show, without specifying how much was paid.
